Fosaprepitant for Injection — Competitive Intelligence Brief

Fosaprepitant for Injection (Fosaprepitant for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NK1 receptor antagonist. Area: Oncology.

marketed NK1 receptor antagonist NK1 receptor (neurokinin-1 receptor) Oncology Small molecule

Target snapshot

Fosaprepitant for Injection (Fosaprepitant for Injection) — Montefiore Medical Center. Fosaprepitant is an intravenous prodrug that is rapidly converted to aprepitant, a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fosaprepitant for Injection TARGET	Fosaprepitant for Injection	Montefiore Medical Center	marketed	NK1 receptor antagonist	NK1 receptor (neurokinin-1 receptor)
fosnetupitant/ palonosetron	fosnetupitant/ palonosetron	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (substance P receptor) / 5-HT3 receptor
Aprepitant plus Ondansetron	Aprepitant plus Ondansetron	University of Pittsburgh	marketed	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
Akynzeo solution	Akynzeo solution	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)
Aprepitant+Tropisetron	Aprepitant+Tropisetron	Sun Yat-sen University	phase 3	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (tropisetron)
Pro-netupitant/Palonosetron	Pro-netupitant/Palonosetron	Helsinn Healthcare SA	phase 3	NK1 receptor antagonist and 5-HT3 receptor antagonist	NK1 receptor and 5-HT3 receptor
NOVA22007	NOVA22007	Santen SAS	phase 3	NK1 receptor antagonist	NK1 receptor (neurokinin-1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NK1 receptor antagonist class)

1. Merck Sharp & Dohme LLC · 4 drugs in this class
2. GlaxoSmithKline · 3 drugs in this class
3. Organon and Co · 3 drugs in this class
4. CCTU · 2 drugs in this class
5. Acacia Pharma Ltd · 2 drugs in this class
6. Sanofi · 1 drug in this class
7. Santen SAS · 1 drug in this class
8. CR-CSSS Champlain-Charles-Le Moyne · 1 drug in this class
9. Montefiore Medical Center · 1 drug in this class
10. New Mexico Cancer Research Alliance · 1 drug in this class